Velocity Clinical Research has announced a collaboration with Verified Clinical Trials (VCT) to address the challenge of double enrolment of subjects in clinical trials.
The implementation of VCT’s participant verification technology across Velocity’s sites ensures that no subject can enrol in multiple studies simultaneously. Velocity own more than 80 different sites.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This technology is a significant step forward in maintaining subject safety and data reliability, as it eliminates the risks associated with double enrolment.
Double enrolment in trials can have severe consequences, including ‘jeopardising’ subjects’ health and significantly increasing drug development costs.
By integrating VCT’s system, Velocity demonstrates its commitment to safeguarding participant well-being and upholding the integrity of clinical research outcomes.
The partnership leverages Advarra’s Clinical Conductor clinical trial management system, which facilitates the seamless processing of enrolment status data through its application programming interface (API).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis integration claims to enhance the pre-screening and verification processes, minimising administrative workloads and improving accuracy.
VCT co-founder and CEO Dr Mitchell Efros said: “Velocity’s decision to implement this system across all their sites, across four countries and two continents, underscores their leadership in patient safety and data integrity.
“This initiative is a powerful response to the growing issue of duplicate enrolment and professional participants, setting a higher standard for the industry.”
Contract research organisations (CROs) and sponsors collaborating with Velocity now have the added confidence of quality data and patient protection.
Velocity Clinical Research chief operations officer Nick Spittal said: “Clinical trial protocols exist to protect participants, but navigating eligibility requirements can be confusing. Some participants may inadvertently enrol in multiple trials, putting themselves and the research at risk.
“This partnership ensures that our sponsors receive the highest quality data while safeguarding participant safety, and is just another example of how scaling for a purpose introduces new benefits to the clinical research industry at large.”
In December 2023, Velocity expanded into Poland with a new site, offering access to a quarter of a million potential subjects.
